Experts debate second-line tivozanib for advanced renal cell carcinoma, weighing PFS gains, tolerability, and whether continuing immunotherapy adds real benefit.
News|Articles|February 12, 2025
What Community Oncologists Should Watch for at ASCO GU 2025
Author(s)Jordyn Sava
Fact checked by: Jason M. Broderick
As the 2025 ASCO Genitourinary Cancers Symposium approaches, several highly anticipated studies are set to shape the future of treatment for prostate, kidney, bladder, and other genitourinary cancers.
Advertisement
Advertisement
As the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) approaches, several highly anticipated studies are set to shape the future of treatment for prostate, kidney, bladder, and other genitourinary cancers. Here’s a roundup of the key trials to watch out for at the meeting:
Related to this article
Preview the late-breaking studies at ESMO Congress 2026, from KRAS inhibitors and ADCs to bispecifics and perioperative immunotherapy across tumor types.
FDA expands nogapendekin alfa inbakicept plus BCG use to high-grade papillary-only BCG-unresponsive NMIBC, offering durable control and strong cystectomy-avoidance outcomes.
Experts weigh IO-TKI vs dual immunotherapy for metastatic ccRCC, highlighting rapid symptom relief, bone/brain response, survival outcomes, and toxicity tradeoffs.
Multiple oncologists share their perspectives on what is still limiting access to CAR T-cell therapies in 2026.
Breakthrough targeted therapies—from KRAS and PROTACs to CAR T—plus ctDNA monitoring and personalized vaccines push earlier detection and smarter cancer treatment.
J. Thaddeus Beck, MD, discusses how the shift from intravenous to subcutaneous formulations is changing oncology practice, from clinic logistics to patient preferences.
The designation expands the investigational immunotherapy’s development across tumor types for patients whose disease progresses after prior treatment, including immune checkpoint inhibition.
Advertisement
Advertisement